REVIEWED COMPANY
NewLimit
Biotechnology research combining epigenetic reprogramming, genomics, and machine learning.
What NewLimit does
NewLimit researches epigenetic reprogramming medicines for age-related diseases. Its discovery process combines machine learning models with genomics experiments to design and test biological payloads, then uses experimental results to refine its models. The company describes research programs focused on liver, immune, and vascular cells. Its work remains in research and development, with clinical trials planned for its initial program. NewLimit is headquartered in South San Francisco, California.